PRESS KIT

Media Contact:
Todd Aydelotte
Ricochet Public Relations
todd@ricochetpr.com
International: 44 -79-243-28536
U.S.: 940-603-3041
Images and video available at www.adultstemcellconference.org
9 November, 2011

Dear Media Partner,

Thank you for your interest in the Adult Stem Cell Research and Awareness Partnership between the Pontifical Council for Culture and NeoStem, Inc./The Stem for Life Foundation. We are extremely grateful for the integrity and accuracy that you bring to the challenge of helping our organizations raise awareness of the paradigm shift that is currently occurring in the world through the expansion of regenerative medicine with adult stem cells. Your contribution is extremely valued and we look forward to a long and healthy partnership with the media.

We welcome you to make use of the materials in this media packet.

Thank you again for your support through media coverage.

Sincerely,

Rev. Tomasz Trafny
Head of Science and Faith Department
Executive Director of STOQ Project
Pontifical Council for Culture

Dr. Robin L. Smith, MD, MBA
Chairman and CEO, NeoStem Inc.
President, Stem for Life Foundation
Press Kit Table of Contents

1. Mission Statement
2. Conference Program Description
3. Partner Organizations
4. Adult Stem Cell Overview
5. Fact Sheet
6. Leadership / Press Conference Bios & Photos
7. Conference Agenda
8. Press Conference Statement by Dr. Robin L. Smith, Chairman and CEO of NeoStem, Inc.
9. May 2010 Press Releases Announcing the Partnership
Partnership between the Pontifical Council for Culture and NeoStem

MISSION STATEMENT

To foster the highest levels of scientific research on adult stem cells and to explore the cultural, ethical and human implications of their use.

Furthermore, we seek to:

Create awareness about the promise of scientific research in concordance with ethical values through the further development of adult stem cell technology.

Determine short-term and long-term actions which political, scientific, educational and religious leaders can take to be part of the cultural paradigm shift arising from the next wave of regenerative medicine.

Lay the groundwork for a collaborative network of scientists and patrons who embrace the promise of adult stem cells to reduce human suffering.

Advance scientific research on adult stem cells and explore their clinical application in the field of regenerative medicine, as well as the cultural impact of such research.
The International Vatican Conference

Adult Stem Cells: Science and the Future of Man and Culture

November 9-11, 2011 - Vatican City

The Vatican Conference will kick off an ongoing initiative between the Stem for Life Foundation, the non-profit foundation of NeoStem, Inc., and the Pontifical Council for Culture to expand research and raise awareness of adult stem cell therapies.

Conference speakers and participants will include the foremost experts in adult stem cell research and recognized leaders in medicine. Attendees will include Church and scientific leaders, policymakers, ethicists, educators, Ministers of Health from around the world, ambassadors to the Holy See and representatives of the stem cell therapeutic business community.

Through keynote speakers, panel discussions, patient case studies, video and breakout sessions, we will create greater awareness of adult stem cells and their applications, explore the latest research and developments in the field, and discuss and debate the implications for the future of culture, medicine, religion and public policy. The event will reach an even wider audience than its 350 invited guests through radio and television broadcast. It is our hope that this Conference will accelerate, support and show the acceptance of man’s unique and truly remarkable adult stem cells for healing.

The Conference will cover three primary areas:

- Clinical applications of adult stem cell science
- Ethical considerations of regenerative medicine
- Cultural implications of regenerative medicine including its social and cultural impact and education

The Conference program will feature:

- Expert presentations on the state of adult stem cell science
- Keynote speakers
- Interactive discussions on the scientific, cultural and ethical implications
- Special receptions for all participants
- Exhibits by commercial and institutional participants
- Special visits inside The Vatican
Our joint mission is:

*To foster the highest levels of scientific research on Adult Stem Cells and to explore the cultural, ethical and human implications of their use.*

This will be achieved through a series of international initiatives being developed by the non-profit Stem for Life Foundation in collaboration with STOQ International, under the auspices of The Vatican’s Pontifical Council for Culture.

**NeoStem**

NeoStem, Inc. (“NeoStem”) is a leader in the development and manufacture of cell therapies. NeoStem has a strategic combination of revenues, including that which is derived from the contract manufacturing services performed by Progenitor Cell Therapy, LLC, a NeoStem company. That manufacturing base is one of the few cGMP facilities available for contracting in the burgeoning cell therapy industry, and it is the combination of PCT’s core expertise in manufacturing and NeoStem’s extensive research capabilities that positions the company as a leader in cell therapy development. Amorcyte, Inc., also a NeoStem company, is developing a cell therapy for the treatment of cardiovascular disease. Amorcyte’s lead compound, AMR 001, represents NeoStem’s most clinically advanced therapeutic, poised to commence enrollment in a Phase 2 trial for the preservation of heart function after a heart attack. Amorcyte is flanked by Athelos Corporation, another NeoStem company, that is developing a T-cell therapy for a range of autoimmune conditions. NeoStem’s pre-clinical assets include its VSEL™ Technology platform for regenerative medicine, which NeoStem believes is an endogenous pluripotent non-embryonic cell that has the potential to change the paradigm of cell therapy as we know it today.

For more information, please visit: [www.neostem.com](http://www.neostem.com).

**The Stem for Life Foundation**

The non-partisan Stem for Life Foundation (SFLF), a tax-exempt 501(c)3 organization, was established to increase public education in all areas of Adult Stem Cell research and application. Its goals are to encourage and support the field of research involving Adult Stem Cells and to provide medicine’s most vulnerable populations with access to key technologies. SFLF’s key activities are education, clinical research support and bio-insurance for first responders and military personnel.

Through working with Science, Theology and Ontological Quest (STOQ) Inter-national, SFLF will direct an educational campaign designed to increase understanding of the cultural applicability of emerging technologies and establish new theological, philosophical and bioethical education programs.
SFLF is dedicated to helping advance the science of Adult Stem Cell research. Through fundraising activities, SFLF will provide financial support to vital clinical trials on the brink of groundbreaking discoveries.

SFLF believes that banking cells for autologous use is a vital form of bio-insurance that must be provided to first responders and the military. SFLF is developing community-based programs to raise the funds needed for local first responders and military to have their Adult Stem Cells extracted and stored for a ten-year period. By doing so, we will be “protecting those who protect us.”

To learn more about SFLF please visit: www.stemforlifefoundation.com.

Pontifical Council for Culture

John Paul II founded the Pontifical Council for Culture in 1982, building on the riches inherited from Pope Paul VI, the Second Vatican Council and the Synod of Bishops.

The Pontifical Council for Culture is that department (Dicastery) of the Roman Curia that assists the Pontiff in the exercise of his supreme pastoral office for the benefit and service of the universal Church and of particular Churches concerning the encounter between the Gospel and cultures. In particular, it promotes dialogue with contemporary cultures, so that human civilization may become increasingly open to the Gospel and so that men and women of science, letters and the arts may know that the Church acknowledges their work as a service to truth, goodness and beauty.

STOQ International

STOQ International is a non-profit 501(c)3 tax-exempt organization operating in the U.S. for the purpose of creating important dialogue between the Church and contemporary culture, which is strongly shaped by scientific advancements.

We change the debate in the arena of ideas related to Theology, Philosophy and present-day Science. We support and encourage scientific research, educational programs and cultural initiatives. The alliance of experts from the disciplines of science, theology and philosophy that form the STOQ Project provokes a renewal of thinking about God and man, creation and providence. We challenge the public perception of the relationship between the Church tradition and science, and we prove the compatibility of faith and reason in the pursuit of knowledge.

The purpose of STOQ is to endorse and conduct an interdisciplinary dialogue in order to build a culture that promotes the full dignity of humanity. Our mission is to build a bridge between science and theology and provide for their positive impact on contemporary society.

We conduct studies through joint research projects, conferences and educational & cultural enterprises.
We continually inform the public, through the leaders, opinion makers, publications and public relations & media resources, that the STOQ Network embraces many institutions worldwide receptive to their ideas.

To know more about STOQ, please visit: www.stoqinternational.org
**Adult Stem Cell Overview**

**What are Stem Cells?**
There are two primary types of stem cells, embryonic and adult stem cells. Stem cells have the remarkable potential to develop into many different cell types in the body during early life and growth. In addition, in many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive. When a stem cell divides, each new cell has the potential either to remain a stem cell or become another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain cell.

Stem cells are distinguished from other cell types by two important characteristics. First, they are unspecialized cells capable of renewing themselves through cell division, sometimes after long periods of inactivity. Second, under certain physiologic or experimental conditions, they can be induced to become tissue- or organ-specific cells with special functions. In some organs, such as the gut and bone marrow, stem cells regularly divide to repair and replace worn out or damaged tissues. In other organs, however, such as the pancreas and the heart, stem cells only divide under special conditions.

**What are Adult Stem Cells?**
The adult stem cell is an undifferentiated cell that is found in a differentiated tissue. It has the ability to renew itself and become specialized to yield all the cell types of the tissue from which it originated and, in the appropriate environment, can also becomes a specialized cell of a different tissue. Adult stem cells are capable of self-renewal for the lifetime of the organism.

Sources of adult stem cells have been found in bone marrow, the blood stream, cornea and retina of the eye, the dental pulp of the tooth, liver, skin, gastrointestinal tract, adipose tissue and pancreas. Stem cells offer the possibility of a renewable source of replacement cells and tissues to treat a myriad of diseases, conditions and disabilities.

**Adult Stem Cell Therapies**
Stem cell-based therapies, such as bone marrow transplant, have been around for over 40 years as treatment for cancer and anemia. But only recently have we begun to realize the full potential of Adult Stem Cells for the treatment of a variety of conditions, including heart disease, auto-immune disorders, and orthopedic ailments.

There has been an increase in adult stem cell therapy clinical trials which are showing great promise in
the areas of skin and wound healing, orthopedics, and in treating diseases including peripheral vascular disease, scleroderma, diabetes, congestive heart failure, myocardial infarction, and much more. Industry sources estimates that the global stem cell product market is expected to reach $88 billion by 2014.
Fact Sheet

FAST FACTS:
Name: NeoStem, Inc.
Ticker (Exchange): NBS (NYSE Amex)
Stock Price: $0.68
Market Cap: $66.6 million
Cash: $4.9 million (6/30/11) with $16.5 mn raised 7/22/11
Net Loss (1H2011): $6.1 million*
52-Week Range: $0.55 - $2.12
Avg. Daily Volume: 439,000 (3 months)
Operations: NY, NJ, MA, CA, China

*All figures as of 10/24/11, except where noted
*Excludes non-cash charges

A Global Leader in Cell Therapy
NeoStem is a leader in the development and manufacture of cell therapies. The Company’s strategic combination of revenues with manufacturing through its subsidiary, Progenitor Cell Therapy, LLC, has positioned the company to be a leader in the cell therapy industry.

Established Leader in Cell Therapy Services
PCT provides NeoStem with manufacturing, regulatory affairs and commercialization expertise that will support the company’s goal to be a leading provider of cell-based therapeutics. In addition, as the product candidates of PCT’s contract manufacturing clients advance through development towards commercialization, NeoStem will benefit from the rising revenues and associated free cash flow.

- 150 years of combined management expertise in manufacturing, regulatory and commercialization for therapeutics development
- East coast and west coast cGMP manufacturing facilities with Asia presence
- “Who’s who” list of the cell therapy industry’s top clients
- $8-10 million in annual historic revenues
- Founded Amorcyte, Inc. (cardiovascular programs) and Athelos Corporation (T-reg programs)
- Principal manufacturer for Provenge, the first FDA approved cancer vaccine, for over 7 year clinical trial period
Emerging Leader in Cardiovascular Cell Therapy

- NeoStem acquired Amorcyte on October 17, 2011
- Lead product, AMR-001, an autologous adult stem cell therapy for the prevention of major adverse cardiac events following acute myocardial infarction (AMI)
- AMR-001 completed Phase 1 clinical trials demonstrating feasibility, safety and biologic activity
- First prospective stem cell trial in AMI ever conducted that has established a significant relationship between dose and effect
- Launching Phase 2 clinical trial by Q1 2012
- Data expected 18 months from the first patient’s enrollment
- Dominant IP position in cardiovascular including composition of matter through 2028

Scientific advisory board affiliations include Brigham & Women’s Hospital, the Mayo Clinic, University of Texas Health Science Center, and Stanford University

Emerging Leader in Immunotherapy

- Immune mediated diseases are a result of imbalance between T effector cells and T regulatory cells
- T-reg therapy represents a novel approach for restoring immune balance by enhancing T-reg cell number/function
- Becton Dickinson owns 20% of the company
- Potential applications include GvHD, solid organ rejection, and autoimmune disease, such as asthma and diabetes
- Scientific advisory board affiliations include University of Michigan, University of California - San Francisco, University of Southern California, University of California - Perelman School of Medicine, and BD Biosciences

Opportunities in Regenerative Medicine

- Worldwide exclusive license to VSEL™ Technology
- Very small embryonic-like stem cells, shown to have several characteristics generally found in embryonic stem cells
- Establishing efficacy of VSELs in preclinical work
- Current ongoing R&D efforts target osteoporosis and bone regeneration, macular degeneration and glaucoma, chronic wound healing, and motor neurons
• Scientific advisory board affiliations include University of Louisville, Roger Williams Medical Centre, and Dana-Farber Cancer Center

Additional Revenue-Generating Businesses

• NeoStem Family Storage
  o Stem cell collection and storage for infants and adults

• Commercializing MSCs in China through hospital partnerships
  o Asia-licensed adult stem cell technology for orthopedic conditions
  o Includes Wendeng, Shijiazhuang, and Tianjin Nankai Hospitals

• 51% Ownership of Suzhou Erye, a generic pharmaceutical company
  o Sales have more than doubled from 2007 to 2010
  o Completing relocation to new 15,000 m2 facility, doubling capacity
  o Over $65 mn in revenues and $4-10 mn historical net earnings

Unique Collaborations

• Becton Dickinson (Athelos)
• Department of Defense (Osteoporosis)
• U.S. Army Medical Research and Materiel Command (traumatic wound healing)
• The Vatican’s Pontifical Council for Culture (exclusive five year partnership to advance adult stem cell research and educate the public, $1 million pledged by The Vatican to initiate activities)
• Academic collaborators include University of Michigan, University of Louisville, Schepens Eye Research Institute (Harvard University)

On the Horizon

• Vatican Adult Stem Cell Conference (Nov. 9-11, 2011)
• Enroll first patient in Phase 2 AMR-001 trial (1Q2012)
• Planned divestiture of Erye
• Advance T-Reg program into the clinic
• Start Phase 1 trial in CHF with AMR-001

NeoStem’s Clinical Development Philosophy

We strive to deliver not just a product that works, but one that creates a compelling pharmacoeconomic benefit and is consistent with best practices of clinical medicine. By conforming to traditional standards
of drug development, we hope to efficiently meet both the government and private payer requirements for approval and reimbursement.

For every therapy, we ask basic scientific questions, such as:

- What is the “active ingredient”? What is the biological mechanism of action?
- What is the biological threshold dose? What is the expected clinical outcome?
Cardinal Gianfranco Ravasi

Cardinal Gianfranco Ravasi is an Italian prelate, a cardinal of the Roman Catholic Church. He currently serves in the Roman Curia as president of the Pontifical Council for Culture.

He attended the seminary of Milan, and was ordained as a priest on June 28, 1966. He continued his studies in Rome at the Pontifical Gregorian University and the Pontifical Biblical Institute. He spent summers in Syria, Jordan, Iraq and Turkey, working as an archaeologist with such figures as Kathleen Kenyon and Roland de Vaux. He later served as a professor of exegesis of the Old Testament at the Theological Faculty of Northern Italy in Milan. From 1989 to 2007, he was prefect of the Ambrosian Library.

In 2007, at the invitation of Pope Benedict XVI, he composed the Good Friday meditations for the public procession of Stations of the Cross led by the Pope at the Colosseum. On September 3, 2007, Ravasi was appointed president of the Pontifical Council for Culture and Titular Archbishop of Villamagna in Proconsulari. He was also named president of the Pontifical Commission for the Cultural Heritage of the Church and of the Pontifical Commission for Sacred Archeology. He received his Episcopal consecration as an archbishop on the following September 29 from Benedict XVI.

On November 20, 2010, Ravasi was created cardinal by Pope Benedict XVI.
Secretary Thompson focuses on developing solutions for clients in the health care industry, as well as for companies doing business in the public sector.

Before entering the private sector in 2005, Secretary Thompson enjoyed a long and distinguished career in public service in the United States. In 1966, he won a seat in Wisconsin’s State Assembly. He became Assistant Assembly Minority Leader in 1973 and Assembly Minority Leader in 1981. Elected Governor of Wisconsin in 1986, he was reelected in 1990, and in 1994 became the first governor in the state’s history to be elected to a third four-year term. In 1998, he was elected to a fourth term, and served in that position until his appointment as Secretary of Health and Human Services in 2001.

As the head of the U.S. Department of Health and Human Services, Secretary Thompson served as the nation’s leading advocate for the health and welfare of all Americans. He worked to modernize and add prescription drug coverage to Medicare for the first time in the program’s history. A leading advocate of welfare reform, he also focused on expanding services to seniors, the disabled, and low-income Americans.
As governor of Wisconsin, Secretary Thompson was perhaps best known for his efforts to revitalize the Wisconsin economy, for his national leadership on welfare reform and for his work in expanding health care access across all segments of society.

Secretary Thompson is well known for his contributions to the U.S. response to the threat of bioterrorism and for his leadership in the fight against HIV/AIDS in the United States and abroad, and he is chairman emeritus of The Global Fund to Fight AIDS, Tuberculosis and Malaria.

Secretary Thompson has received numerous awards for his public service, including the Anti-Defamation League’s Distinguished Public Service Award, Governing magazine’s Public Official of the Year Award and the Horatio Alger Award, which is awarded annually to “dedicated community leaders who demonstrate individual initiative and a commitment to excellence—as exemplified by remarkable achievements accomplished through honesty, hard work, self-reliance, and perseverance.” He is a former chairman of the National Governors’ Association, the Education Commission of the States, and the Midwestern Governors’ Conference.

Secretary Thompson received both his B.S. in 1963 and his J.D. in 1966 from the University of Wisconsin-Madison. He is a member of the District of Columbia and Wisconsin Bars.
Reverend Tomasz Trafny

Rev. Trafny completed his studies in philosophy and theology at the Catholic University of Lublin. Ordained as a priest in 1996 for the Archdiocese of Lublin, he served as a parish assistant in Kazimierz Dolny (Archdiocese of Lublin), as a chaplain at the Hospice for Terminally Ill Patients, and as a chaplain at the Medical University of Lublin. He continued his postgraduate studies in philosophy at the Catholic University of Lublin and afterwards at the Pontifical Lateran University in Rome.

Since 2006, he has served as the official at the Pontifical Council for Culture, head of Science and Faith Department (Vatican City State) and executive director of STOQ Project. His focus is on matters related to the wide-ranging dialogue between science and religion, especially cultural analysis of scientific advancements, but his interests also include philosophy and theology of nature as well as environmental and climate change issues. He is director of the STOQ Project Research Series and chairman of STOQ International (www.stoqinternational.org).
Dr. Smith joined NeoStem, Inc., as chairman of its Advisory Board in September 2005 and, effective June 2, 2006, became the chief executive officer and chairman of the Board of Directors. Dr. Smith, who received a medical degree from Yale University in 1992 and a master’s degree in business administration from the Wharton School of the University of Pennsylvania in 1997, brings to NeoStem extensive experience in medical enterprises and business development. From 2000 to 2003, Dr. Smith served as president and chief executive officer of IP2M, a multi-platform media company specializing in healthcare. During her term, the company was selected as being one of the 10 fastest growing technology companies in Houston, Texas. IP2M was sold to a publicly traded company in February 2003. Previously, from 1998 to 2000, she was executive vice president and chief medical officer for HealthHelp, Inc., a national radiology management company that managed 14 percent of the healthcare dollars spent by large insurance companies.

Dr. Smith has acted as a senior advisor to, and investor in, both publicly traded and privately held companies including, but not limited to, China Biopharmaceuticals Holdings, Inc., the Madelin Fund, HC Innovations, Inc., Navstar Media Holdings, Strike Force, Health Quest, Red Lion Partners and All American Pet, where she played a significant role in restructuring and/or growing the companies. Dr. Smith served on the Board of Directors of two privately held companies, Talon Air and Biomega, and
also served on the Chemotherapy Foundation Board of Trustees and The New York Theatre Ballet. She currently serves on the Board of Trustees of the New York University Medical Center, is past chairman of the Board of Directors for the New York University Hospital for Joint Diseases where she headed up new development efforts and board member recruitment, and served on the Board of Choose Living. Dr. Smith is the president and serves on the Board of Directors of The Stem for Life Foundation.
CONFERENCE SCHEDULE

The Conference Schedule may change due to the Papal Audience that was requested

Wednesday, November 9, 2011 – Opening Day

OPENING SESSION

9:30 a.m.  Attendee Arrival at Aula Nuova del Sinodo

10:00 a.m.  Greetings

Cardinal Gianfranco Ravasi, President of the Pontifical Council for Culture

10:20 a.m.  Welcome and Overview of the Conference

Dr. Robin L. Smith, Chairman and CEO of NeoStem, Inc., President and Trustee of the Stem for Life Foundation

10:45 a.m.  Prolusion

H.E. Msgr. Ignacio Carrasco de Paula, President of the Pontifical Academy for Life

GENERAL OVERVIEW

11:15 a.m.  The Promise of Stem Cells: Where are we Today and Where Will we be in the Future?

Dr. Max Gomez, Trustee of the Stem for Life Foundation

Clinical Patient: Heather Abrams

11:45 a.m.  Stem Cell Medicine: Social and Political Challenges

Hon. Tommy G. Thompson, Former US Secretary of Health and Human Services

12:30 p.m.  Lunch
Wednesday, November 9, 2011

MEDICAL PERSPECTIVE AND THE CLINIC - PART I

1:45 p.m.  Adult Stem Cell Sources and Types:
- Placental Cells  
  Dr. Robert J. Hariri, CEO of Celgene Cellular Therapeutics
- Very Small Embryonic-Like Stem Cells  
  Dr. Mariusz Z. Ratajczak, University of Louisville
- Induced Pluripotent Stem Cells  
  Dr. Peter Coffey, University College of London

2:45 p.m.  Panel Discussion: Past Practices: Cord Blood and Bone Marrow Transplantation for Hematological Disorders
Moderator:  
Dr. Andrew L. Pecora, Chief Medical Officer of NeoStem, Inc.
Panelists:  
Dr. Claudio Bordignon, Chief Executive Officer of MolMed
Dr. Mitchell S. Cairo, New York Medical College
Dr. Stephen D. Nimer, Memorial Sloan-Kettering Cancer Center
Dr. John Wagner, University of Minnesota Center for Translational Medicine
Clinical Patient:  
Stephen R. Sprague

4:30 p.m.  The Pharmacy of the Future: Cells, Not Pills  
Dr. Robert A. Preti, President of Progenitor Cell Therapy, LLC.

5:00 p.m.  Closing Remarks

5:30 p.m.  Visit to the Sistine Chapel

8:00 p.m.  Cocktail Reception at the Vatican Museums
Thursday, November 10, 2011

MEDICAL PERSPECTIVE AND THE CLINIC – PART II

9:00 a.m.  Opening Remarks
Dr. Robin L. Smith, Chairman and CEO of NeoStem, Inc., President and Trustee of the Stem for Life Foundation

9:05 a.m.  Clinical Focus: Cardiovascular Disease
Moderator:
Dr. Douglas W. Losordo, VP, Medical Director of New Therapies, Baxter Healthcare
Panelists:
Dr. Atul R. Chugh, University of Louisville
Dr. Keith L. March, Indiana University
Dr. Hung-Fat Tse, University of Hong Kong
Clinical Patient:
Charles Melber

10:25 a.m.  Clinical Focus: Organ and Tissue Regeneration
Dr. Anthony Atala, Wake Forest Institute for Regenerative Medicine
Dr. Christopher J. Centeno, Centeno-Schultz Clinic

11:15 a.m.  Break

11:30 a.m.  Adult Stem Cell Sources and Types:
Mesenchymal Stem Cells, Dr. Neil Scolding, University of Bristol
ELA® Stem Cells, Dr. Keith D. Crawford, Harvard Medical School

12:15 p.m.  Lunch

1:45 p.m.  Clinical Focus: Autoimmune Disease
Dr. Richard K. Burt, Northwestern University
Clinical Patient: Sharon Porter

2:30 p.m.  Personalized Medicine and Stem Cells Health
Dr. Wayne A. Marasco, Dana-Farber Cancer Institute
Dr. Nadia Rosenthal, Australian Regenerative Medicine Institute, Monash University

3:15 p.m.  Break
Thursday, November 10, 2011

MOVING FROM THE MEDICAL TO THE BIOETHICAL DIMENSION

3:30 p.m.  Building Relationships between the Church and the Adult Stem Cell Community and its Stakeholders
Rev. Tomasz Trafny, Head of Science and Faith Department - Pontifical Council for Culture
H.E. Msgr Vincenzo Paglia, Terni-Narni-Amelia, Italy

4:15 p.m.  Discussion on Bioethics
Moderator:
Dr. Arthur L. Caplan, University of Pennsylvania Center for Bioethics
Panelists:
Dr. David A. Prentice, John Paul II Institute of the Catholic University of America
Dr. Peter Hollands, University of Westminster

5:30 p.m.  Closing Remarks

5:45 p.m.  Speaker Dinner at Casina Pio IV in the Vatican Gardens
CULTURAL DIMENSION: EDUCATIONAL AND PHILOSOPHICAL EFFORTS

9:00 a.m.  Opening Remarks  
*Dr. Max Gomez, Trustee of the Stem for Life Foundation*

9:05 a.m.  Education as a Challenge: Necessary Tool for a Better Future  
*Prof. Anthony J. Cernera, President of the International Federation of Catholic Universities*

9:30 a.m.  Should the Hippocratic Oath be Extended to Life Sciences?  
*Prof. Phillip R. Sloan, University of Notre Dame*

10:00 a.m.  Break

10:15 a.m.  Will the Advancement of Life Sciences Change Our Vision of Man  
*Rev. Nicanor Pier Giorgio Austriaco, Providence College*

10:45 a.m.  Humanism: Necessary Conditions for Optimization  
*Rev. Kevin FitzGerald, Georgetown University*

11:15 a.m.  Closing Session: Next Steps in Our Mission  
*Dr. Robin L. Smith, Chairman and CEO of NeoStem, Inc., President and Trustee of the Stem for Life Foundation*

12:00 p.m.  Official Close of Conference

OPTIONAL ACTIVITIES

2:30 – 5:30 p.m.  Cultural Tours of the Highlights of Rome

8:30 p.m.  The Sistine Chapel Choir - Concert at the Basilica of St. John Lateran  
*Harmonies of the Spirit: Musical Meditations for Italian Basilicas*
Press Conference Statement by Robin L. Smith MD, MBA

On behalf of NeoStem, our shareholders and the Stem for Life Foundation, I’m so honored to be here today and would like to offer my sincere appreciation for the vision and leadership of Cardinal Ravasi and the Vatican Pontifical Council for Culture, and for the support of the Pontifical Council for Health Care Workers and the Pontifical Academy of Life.

Rome is the birthplace of many of the world’s greatest ideas. Here we can find the works of Michelangelo and Caravaggio, and some of our best poets, architects and philosophers. It is the birthplace of some of the first public health programs and the development of aqueducts and sewage systems — innovations that have helped control the spread of dangerous disease.

I think adult stem cells are another great classical masterpiece. But this masterpiece is not made with human hands — they are already inside of our own bodies, just waiting to be used to combat deadly disease and dangerous medical conditions.

We are making history as NeoStem joins hands with the Vatican, STOQ International and the Stem for Life Foundation. Together we’re embarking on a multi-year journey to usher in a new era of regenerative medicine. And at the heart of our partnership lies a very simple idea — by uniting our forces we can produce the biggest social impact. At this conference, we will have political leaders and governmental representatives from around the world, Ambassadors to The Holy See, European parliamentarians, and members of international organizations like UNESCO. We will have the world’s leading scientists in adult stem cell medicine, as well as business leaders, dignitaries, doctors and patients who have benefited from adult stem cell therapies. We have theologians, including Cardinal Ravasi and Monsignor Ignacio Carrasco de Paula of the Vatican.

We will be many voices joined together. And our cause is urgent. Right now, there are more than 12.7 million people living with some form of cancer and 346 million living with diabetes. And autoimmune disorders now affect over 583 million people worldwide. These diseases, which include Lupus, Multiple Sclerosis, leukemia, bladder cancer and cardiovascular insufficiency and many others, can be debilitating and life threatening.

But behind each of those statistics are real people — and a lot of hope.

I would like to tell you about Bethany Pappalardo, a college freshman who was suffering from multiple sclerosis. Every day Bethany lived in fear that a new attack would strike. And one morning she woke up and felt numbness in her legs. By the end of that day she was numb from the neck down. A young woman with the world in front of her saw her health slipping away. Five years ago Bethany had an adult stem cell transplant and, since then, her MS attacks have stopped and today she is living a normal, happy life. Adult stem cells rebooted her immune system, harnessing the power of her own body to keep this deadly disease in check. We are honored that her doctor, Richard Burt will join us at this summit to share advances in using adult stem cell therapy to treat autoimmune disorders.
Another patient, Stephen Sprague, contracted Chronic Myelogenous Leukemia fourteen years ago. He was in blast crisis giving him 3-6 month to live. Being turned away by other physicians, Stephen found Dr. Andrew Pecora and, with the assistance of Dr. Robert Preti, the FDA granted special permission for a one time compassionate use that leveraged technology developed to expand the adult stem cells from a single umbilical cord blood unit. After chemotherapy, Mr. Sprague’s immune system was rebuilt and reconstituted. Today these doctors and Stephen Sprague himself gather to tell the story of their incredible journey and how the field has advanced over the past decade.

In the not too distant future we will be able to use adult stem cells to rebuild damaged tissue and repair organs such as the heart. Today technologies are being rapidly developed, such as Amorcyte’s lead product, AMR-001 designed to treat patients six to ten days after an acute heart attack to prevent adverse remodeling and worsening of cardiac function leading to premature death.

These miracles come without the ethical dilemma posed by the use of embryonic stem cells. Adult stem cell research and therapy allow us to advance scientific knowledge while protecting every stage of existence. Advances need resources and tomorrow we will announce the extraordinary individual who will be the recipient of the Key Guardian Award at a very special event planned in 2012. This award honors a corporation, institution or individual for their efforts to increase the well being of humankind through their support of new innovative sciences and medicine. This individual’s generous support of cutting edge technologies gives all of us resources and hope.

We must also say a special thank you to Father Trafny for his incredible dedication to understand the impact of scientific discovery on culture, and lead the effort to improve humanity by uniting science and faith. We are privileged to have the Honorable Tommy Thompson, former U.S. Secretary of Health and Human Services and governor of Wisconsin, who will share with all of us how policy and economics shape our health care system. Through Tommy’s unique understanding of what these therapies might mean to modern day healthcare, he can guide us on how we can successfully advance new discoveries from the lab into the clinic in a complicated political environment.

It’s certainly going to be an historic three days. This is just the beginning of our mission over the next four years is to educate society about the therapeutic potential of adult stem cells, to advance adult stem cell therapies, and to understand the impact this new medicine will have on culture and the impact it will have on people’s faith to unite and end human suffering.
Breakthrough: The Pontifical Council for Culture and NeoStem Partner to Advance Adult Stem Cell Research

NEW YORK, NY – May 26, 2010 - In a press briefing in New York, Reverend Tomasz Trafny of The Vatican's Pontifical Council for Culture announced what he characterized as The Vatican's first-ever contractual collaboration with an outside commercial venture to advance stem cell research – adult stem cell research.

Reverend Trafny also revealed that the Pontifical Council for Culture through its charitable foundation STOQ International, is making an economic commitment of one million dollars to start its collaboration with NeoStem (NYSE Amex: NBS), an international biopharmaceutical company with operations in the US and China. Dr. Robin Smith, CEO of NeoStem, made the announcement along with Reverend Trafny.

This initiative will partner NeoStem's and The Vatican's charitable organizations to expand research and raise awareness of adult stem cell therapies. The initiative will entail work on a variety of collaborative activities with the goal of advancing scientific research on adult stem cells and exploring their clinical application in the field of regenerative medicine, as well as the cultural impact of such research.

NeoStem acquired the worldwide exclusive rights to VSEL™ technology in 2007. Very small embryonic-like stem cells, which form the basis of the VSEL™ technology, have physical characteristics typically found in embryonic stem cells, including the ability to differentiate into specialized cells found in different types of tissue that would be able to interact with the specific organ in order to repair degenerated, damaged or diseased tissue. This technology addressed in this collaboration with The Vatican opens the door to the possibility of achieving the positive benefits associated with embryonic stem cells without the ethical or moral dilemmas as well as other negative effects associated with embryonic stem cells.

"For more than 40 years, physicians have been using adult stem cells to treat various blood cancers, but only recently has the promise of using adult stem cells to treat a significant number of other diseases begun to be realized. There are tremendous clinical and economic advantages to autologous stem cell transplantation (receiving your own stem cells) as there are no issues with immune rejection. Engraftment with your own stem cells is faster, safer and much less costly than receiving someone else’s
stem cells (allogeneic)," said Dr. Robin L. Smith, Chairman and CEO of NeoStem. "Providing critical support to drive research and therapy efforts, this commitment is a milestone for the field of regenerative medicine," added Dr. Smith.

In addition to the breakthrough research expected to occur as part of this partnership, The Vatican and NeoStem will spearhead an education campaign geared towards generating awareness of the cultural relevance of such a fundamental shift in medical treatment options, particularly with regard to the impact on theological and ethical issues.

Specifically, NeoStem and the Pontifical Council intend to pursue the development of educational programs, publications and academic courses with an interdisciplinary approach for theological and philosophical faculties, including those of bioethics, around the world.

One of the highlights of this partnership will be a three day International Conference at The Vatican on adult stem cell research, including VSEL™ technology, that will focus on medical research presentations and theological and philosophical considerations and implications of scientific achievements that is planned for November 2011.

The charitable organizations from both partners that specifically will drive activity are NeoStem's Stem for Life Foundation, and the Pontifical Council's Foundation, called STOQ International (Science Theology and the Ontological Quest).

Considering the potential implication of scientific investigation, medical applicability and the cultural impact of research on adult stem cells, we view the collaboration with NeoStem as a critical effort," said Trafny. "Through educational initiatives with NeoStem and sponsorship of scientific research programs involving cutting edge adult stem cell science which does not hurt human life, we come one step closer to a breakthrough that can relieve needless human suffering. We are particularly excited about NeoStem's VSEL™ technology and believe that mutual collaboration between NeoStem and the Pontifical Council for Culture could lead to significant financial commitment to support VSEL™ technology research."

All initiatives will aim at providing information, teaching and research regarding important issues of human health and of the present and future of medical progress in relation to adult stem cell research and with respect to the great value of human life. NeoStem and the Pontifical Council for Culture through their collaboration aspire to reach religious leaders and academicians working in the Pontifical
and Catholic Institutions but also to extend their work and results to different institutions beyond the catholic environment.

**About NeoStem, Inc.**

NeoStem, Inc. is engaged in the development of stem cell-based therapies, pursuit of anti-aging initiatives and building of a network of adult stem cell collection centers in the U.S. and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The Company is also the licensee of various stem cell technologies, including a worldwide exclusive license to VSEL(TM) technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit: [http://www.neostem.com](http://www.neostem.com).

**About The Pontifical Council for Culture**

The Pontifical Council for Culture is that Dicastery of the Roman Curia which assists the Pontiff in the exercise of his supreme pastoral office for the benefit and service of the universal Church and of particular Churches concerning the encounter between the saving message of the Gospel and cultures, in the study of the weighty phenomena of the rift between the Gospel and cultures; indifference in matters of religion; unbelief. It is also concerned with relationships between the Church and the Holy See and the world of culture; in particular it promotes dialogue with contemporary cultures, so that human civilization may become increasingly open to the Gospel, and so that men and women of science, letters and the arts may know that the Church acknowledges their work as a service to truth, goodness and beauty.

Among different tasks that have been given to the Pontifical Council for Culture, some are related to the collaboration with different cultural and scientific institutions. Those tasks are the following:

- To co-operate with Catholic universities and international organisations of a historical, philosophical, theological, scientific, artistic or intellectual nature, and to promote co-operation amongst them (John Paul II, Personal Letter to the Cardinal Secretary of State, 20 May 1982 concerns foundation of the Pontifical Council for Culture).

- To keep up with the activities of international bodies like UNESCO and the Council of Europe, which are concerned with culture, the philosophy of science and human sciences, and to ensure
the effective participation of the Holy See in international congresses concerned with science, culture and education (Cf. ibid.).

- To facilitate Church-culture dialogue at the level of universities and research centres, organisations of artists and specialists, researchers and scholars, and to promote meetings of note in and through these sectors of culture (Cf. ibid.).

Forward-Looking Statements of NeoStem, Inc.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to the initiatives surrounding the collaboration with the Pontifical Council for Culture about which no assurances can be given. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2010, as well as other periodic filings made with the Securities and Exchange Commission. The Company’s further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.